Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jul 13;2:PO.17.00235. doi: 10.1200/PO.17.00235

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Fig 1. — Comparison of rate of MDM2 amplification in the current report (N = 102,878 samples) versus in Genomics Evidence Neoplasia Information Exchange (GENIE; N = 13,473 samples).³¹ Data from GENIE were obtained as previously described.³¹ The 10 most common diagnoses that harbor MDM2 amplification from the current report were selected for the comparison. MDM2 amplifications were seen in 3.5% (3,650 of 102,878) of patients in the current report versus 5.5% (744 of 13,473) from GENIE. MDM2 amplification was most commonly seen in patients with liposarcoma (63.6% [332 of 522] in the current report and 69.1% [47 of 68] from GENIE); gallbladder, adenocarcinoma (11.1% [62 of 554] in the current report and 17.5% [seven of 40] from GENIE); sarcoma, not otherwise specified (10.7% [103 of 955] in the current report and 25.0% [four of 16] from GENIE); urothelial carcinoma (10.4% [198 of 1,898] in the current report and 10.7% [48 of 446] from GENIE); and lung, adenosquamous carcinoma (9.8% [17 of 173] in the current report and 9.0% [one of 11] from GENIE).